Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

INTRODUCTION: Recent studies suggest that docetaxel plus androgen deprivation therapy can prolong survival among men with metastatic hormone-sensitive prostate cancer (mHSPC). However, as a cytotoxic therapy, there is a need to understand the experiences of men with mHSPC receiving docetaxel and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Tetsuro, Grant, Laura, Duckham, Bryony R., Ribbands, Amanda J., Gater, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267709/
https://www.ncbi.nlm.nih.gov/pubmed/30415297
http://dx.doi.org/10.1007/s12325-018-0825-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267709/
https://www.ncbi.nlm.nih.gov/pubmed/30415297
http://dx.doi.org/10.1007/s12325-018-0825-7

Ejemplares similares